The accumulation of CD4 þ T regulatory cells (Treg) in tumor tissue is a widely described phenomenon in mouse models and in human cancer patients. Understanding the mechanisms by which Treg migrate and accumulate in tumors is important because they strongly influence the potential efficacy of many immunotherapies. In this study, we used immunoscope technology to analyze the T-cell receptor (TCR) repertoire of tumorinfiltrating T cells in non-TCR transgenic mice. Both tumor-infiltrating Tregs and T effector cells (Teff) displayed sequence profiles in the CDR3 region that were characteristic of biased repertoires seen during clonal cell expansions, implying that strong T-cell responses have occurred within the tumor tissue. By comparing the TCR sequences of tumor-infiltrating Tregs, we obtained evidence of the presence of so-called public TCR sequences that are common to many individuals yet were tumor-specific in nature. Such comparisons also suggested that the Treg-Teff conversion process is not an active process at the tumor site or tumor-draining lymph nodes. Our findings strongly suggest that Treg infiltration of tumor tissue is followed by marked proliferation of a few dominant T-cell clones in the tumor. Cancer Res; 72(14); 3557-69. Ó2012 AACR.
Introduction

CD4
þ regulatory T cells (Treg) are characterized by the expression of interleukin-2 (IL-2) receptor alpha chain (CD25; ref. 1) and the forkhead box P3 (Foxp3) transcription factor (2, 3) . Numerous studies have shown the central role of Tregs in inducing and maintaining peripheral tolerance through various suppression mechanisms (4, 5) . There is also increasing evidence that Tregs control adaptive immune responses induced by bacteria, viruses, and parasites (6) , as well as in cancer immunity (7) . Although the exact function and contribution of Tregs to tumor immunity remains controversial, their accumulation in tumor tissue is a widely described phenomenon in mouse models and in human cancer patients (8, 9) . Nevertheless, the mechanisms governing this process are poorly understood. One recent study (10) proposed that the rapid recruitment of Tregs and/or expansion into tumors is a consequence of early tumor-cell recognition by memory Tregs specific to self-antigens. Indeed, Tregs have been shown to express a self-reactive TCR repertoire (11) , though it is unclear whether the recruitment and activation of Tregs are nonspecifically induced by the tumor environment or specifically triggered by tumor or selfantigens. The accumulation of Treg in tumors could also result from the conversion of peripheral Foxp3
À T-cells into Foxp3 þ T-cells, a process that has already been described in the gut, requiring TGF-b and retinoic acid (12, 13) .
To address this issue, we used the immunoscope technology to analyze the T-cell receptor (TCR) repertoire of CD4 þ T cells infiltrating tumors (14) in non-TCR transgenic Foxp3-GFP knockin mice bearing TC-1 large solid tumors. Tumor-infiltrating and tumor-draining lymph node (dLN) Tregs and effector T cells (Teffs) were purified, submitted to complementarity-determining region 3 (CDR3) spectratype analysis, and compared with cell populations in peripheral lymph nodes (pLN) or spleen from naive mice. We showed marked alterations in CDR3 length distributions for all of the BV chain families analyzed in Treg and Teff samples from every tumor, which strongly suggests clonal expansion of intratumoral T cells. Moreover, we showed the existence of public sequences shared by all TC-1 tumor-infiltrating Treg samples in 6 independent experiments. These results were also confirmed in another tumor model, MO-5. The public sequences were completely different between the 2 tumor models and were not shared by tumor-infiltrating Teff cells, suggesting that the conversion process is not actively contributing to Treg enrichment of the tumor. This study shows that the TCR repertoire of tumor Tregs in non-TCR transgenic mice is skewed toward public sequences and that Tregs infiltrate tumor tissue through an antigen-driven mechanism that is specific to each tumor model and different from that in Teff cells.
Materials and Methods
Mice and tumors Six-to 8-week-old female Foxp3-GFP knockin mice on C57BL/6 background were kindly donated by B. Malissen (Centre d'Immunologie de Marseille-Luminy, Marseille, France) (15) . Animals were kept under specific pathogen-free conditions at the Pasteur Institute animal facility with water and food ad libitum. All in vivo experiments were conducted according to the institutional guidelines for animal care.
TC-1 tumor cells expressing HPV16-E6 and HPV16-E7 proteins and derived from primary mouse lung epithelial cells were obtained from the American Type Culture Collection (LGC Promochem; ref. 16 ). MO-5 cells, derived from the murine melanoma B16 (OVA transfected) were kindly provided by L. Sigal (University of Massachusetts, Worcester, MA). Tumor cells (1 Â 10 6 TC-1 cells) in 200 mL PBS were injected into the shaved back (right side) of Foxp3-GFP mice. Tumor size, presented as the average of 2 perpendicular diameters (millimeters), was measured at regular intervals with a digital caliper (Mitutoyo).
Cell isolation
pLN (maxillary, axillary, and inguinal) or inguinal tumordLN from naive mice were harvested, mechanically disrupted, and filtered to obtain single-cell suspensions. Spleens were harvested and treated for 45 minutes with 400 U/mL collagenase D and 50 mg/mL DNase I (Boehringer Mannheim), dissociated, and filtered to obtain single-cell suspensions. Tumors were harvested, cut into small pieces, and dissociated using the GentleMacs dissociator programs Spleen-01 and Spleen-04.
Flow cytometry analysis
Cell suspensions were first incubated with rat anti-CD16/32 monoclonal antibodies (mAbs; 2.4G2) to block binding to Fc receptors before staining with diverse fluorescent dye-conjugated mAbs. mAbs used for staining were phycoerythrin-conjugated anti-CD69 (HI.2F) and anti-CD44, PerCP-conjugated anti-CD4 (RM4-5) and anti-CD8, Pacific blue-conjugated anti-CD3, Alexa-780-conjugated anti-CD45.2 and allophycocyanin-conjugated anti-CD62L (MEL-14). Cell viability was determined by 7AAD staining. Foxp3 þ cells were detected either by testing for eGFP expression or with intracellular staining with anti-Foxp3 mAb (FJK-16), in accordance with the manufacturers' protocol (eBioscience). All mAbs were purchased from BD Pharmingen or eBioscience. Cells were acquired on a CyAn (Coultronics) flow cytometer and analyzed by use of FlowJo (Tree Star) software.
Purification of Teff and Treg cells
Lymph nodes, spleens, and tumor-cell suspensions from Foxp3-GFP knockin mice were incubated with anti-CD4-coated magnetic beads (N418 clone; Miltenyi Biotec) according to the manufacturers' instructions. Phycoerythrinconjugated anti-CD4 and allophycocyanin-conjugated antiCD11c were added 10 minutes before the end of the incubation time. After incubation, cells were washed and CD4 þ cells were selected on an automated magnetic cell sorter (AutoMACS; Miltenyi Biotec) using the possels program. Positive fractions, composed of 80% to 95% CD4 þ cells were further sorted into
cells on a Moflo cell-sorter cytometer (Beckman-Coulter). The purity for each cell type was at least 90%.
Quantitative repertoire analysis of BV repertoires Total RNA was extracted from highly purified sorted cell samples, using RNeasy Plus MicroKit (Qiagen). First-strand cDNA synthesis was carried out using oligo-dT and RNase H-reverse transcriptase SuperScript II (Invitrogen). Quantitative analysis was carried out as previously described (17, 18) and as detailed in Supplementary Methods. For immunoscope profiles, products were then subjected to run-off reactions with a nested fluorescent primer specific for the constant region for 3 cycles (see in Supplementary Methods). Fluorescence intensities were plotted in arbitrary units on the y-axis, and CDR3 lengths (determined in amino acids) were plotted on the x-axis (14) .
Quantitative analysis
For each BV TCR family, the immunoscope profile was quantified using the same methodology as described in Gorochov (19) . Briefly, the fraction of the area under each CDR3 length pic, for a specific BV TCR family, was calculated for each sample that was analyzed. Immunoscope profile quantifications from naive spleen samples were used as a control. The extent of perturbation of every CDR3 length pic in a given BV TCR family was calculated by the distance between the analyzed sample and the control. This measure of perturbation was plotted as landscapes obtained with Excel software (Microsoft Corporation).
Cloning and sequencing of CDR3 regions
Total BV8.1/BC-or BV6/BC-amplified products from different cDNA were cloned using the Zero Blunt TOPO PCR Cloning Kit for Sequencing (Invitrogen). Direct sequencing was carried out as previously described (20) and as detailed in Supplementary Methods. Sequences were analyzed using Taps1.1 software (21) . V-D-J junction analysis was done using IMGT/JunctionAnalysis tool (22) , available at IMGT web site (23).
Statistical analysis
Prism software (GraphPad Software, Inc.) was used to calculate statistical significance for the differences of particular measurements between groups. Two-tailed unpaired t test and one-way ANOVA were used; P values less than 0.05 were considered to be statistically significant. 
Results
TC
CD3
þ T cells accounted for less than 10% of these cells from which half were CD4 þ (Fig. 1) . Tregs represented 60%
of tumor-infiltrating CD4 þ T cells (Fig. 1D) , which confirmed our previous observations on wild-type C57BL/6 TC-1 tumorbearing mice (24) . Phenotype analysis identified a drastic downregulation of CD62L expression and a significant upregulation of CD44 and CD69 molecules on tumor Treg cells, compared with splenic and LN populations ( Fig. 1E and F The CDR3 profiles of the BV families obtained from splenic Treg samples from naive mice showed a typical bell-shaped distribution of 6 to 8 distinct CDR3 peaks ranging from 6 to 12-aa in length ( Fig. 2A) . Such Gaussian distributions are typical of a highly diverse repertoire and reflect a lack of clonal expansion. Each BV family was expressed by a percentage of Treg cells ranging from less than 0.1% to more than 15% (BV-16; Supplementary Fig. S5A ). Five different BV families . Quantitative spectratyping analysis of the CDR3 length profiles reveals clonal expansions in TC-1 tumor-infiltrating Treg cells. Foxp3-GFP mice were injected on day 0 with 1 Â 10 6 TC-1 cells. Twenty-five days later, mice were killed and spleens, tumor-dLNs, and tumors were processed to obtain cell suspensions. After AutoMacs CD4 þ cell enrichment, Foxp3-GFP þ Treg cells were FACS sorted, and total RNA was purified and reverse transcribed. The corresponding cDNA material was then subject to quantitative PCR with primers specific to each BV family and the resulting products were subjected to runoff reactions to obtain immunoscope profiles. Spleens and pLNs from naive Foxp3-GFP mice were identically processed and used as controls. were expressed by less than 1% of the total Treg cell population (BV-5.1, BV-5.3, BV17, BV-18, and BV-19, Supplementary  Fig. S5A ). Some alterations in CDR3 peak distributions were observed for these BV families. However, this was due to the very low number of cells bearing these particular BV chains, which was insufficient for reproducible Gaussian distributions.
The CDR3 profiles of Treg cells from naive pLN or spleen in tumor-bearing mice also displayed Gaussian distributions that were very similar to those obtained with naive spleen samples ( Fig. 2 and Supplementary Fig. S2E ). No significant alteration in CDR3 profiles was observed for tumor dLN Treg cells (Fig. 2C) .
In contrast, the CDR3 profiles of Tregs isolated from TC-1 tumors showed drastic alterations in all BV families ( Fig. 2D and Supplementary Fig. S2F-H ), leading to a non-Gaussian distribution. Several BV CDR3 profiles showed only 1 or 1 major CDR3 peaks often corresponding to 6 or 12 aa (amino acid). This contrasted with the usual 8 to 10 aa central CDR3 peaks found on bell-shaped distributions. CDR3 profile alterations were also observed in BV families expressed by a high percentage of tumor Treg cells. In addition, some BV families presenting altered CDR3 profiles have an increased percentage of usage in tumor Treg populations (i.e., BV-8.1: 12.4% in tumor sample 1 and 6.6% in tumor sample 2, vs. 3.4% in naive spleen samples, Supplementary Fig. S5A ), which could reflect clonal expansions.
Biased BV-8.1 BJ usage by tumor Treg cells
Each CDR3 peak may represent hundreds or thousands of different sequences (21) , each coding for a unique TCR with a particular antigen specificity. To determine whether the distortions observed for tumor Treg CDR3 profiles reflected clonal expansions of Treg cells, we analyzed the CDR3 sequences of Treg samples obtained from TC-1 tumor-bearing mice or from naive mice, prepared with identical cell numbers. We selected the BV-8.1 family for this analysis because biased CDR3 profiles-with a major 8-aa CDR3 peak-were observed in all of the tumor Treg samples analyzed (Fig. 2E) . We used Gorochov mathematical analysis to quantify the distance between different CDR3 profiles by calculating the area beneath each peak (19) . This showed that BV-8.1 CDR3 profiles of tumor Treg samples from 6 independent experiments were significantly different from those obtained with Treg samples from naive spleen or pLN or from tumor spleen and dLN (Fig. 2F) .
To determine whether the perturbations observed in the BV-8.1 CDR3 profiles could result from biased BJ gene usage, we determined the percentage of usage of each BJ gene by BV-8.1-expressing Tregs. A significantly increased usage of BJ-2.5 was observed for tumor Treg samples versus naive pLN Treg cells, whereas the usage of BJ-2.3 and BJ-2.7 was markedly decreased (Supplementary Fig. S5B ).
The existence of public sequences in the TCR repertoire of tumor-infiltrating Tregs suggests antigen-driven expansion A total of 646 sequences were obtained from 6 different tumor Treg samples, and we analyzed the frequency of unique CDR3 sequence occurrence in these various samples (Supplementary Table S1 ). In naive pLN samples, only 17.3% of CDR3 sequences were present more than 3 times, and none of them was detected more than 6 times. In contrast, in tumor Treg samples, 37.9% of CDR3 sequences were present more than 3 times with 17.3% of these sequences detected more than 10 times.
To address whether these clonal expansions were driven by the recognition of the same antigen, we thus compared the BV-8.1 TCR sequences of Treg samples from tumors and tumor dLN with naive pLN samples from various independent experiments. First, we compared the pLN sequences from 2 naive mice (229 sequences for N1 and 324 sequences for N2). As expected, only one unique TCR amino acid sequence was shared by these 2 data sets ( Table 1 , top portion).
We applied the same methodology to compare every sequence from tumor Treg data sets with each other and with naive or tumor lymph node data sets. Unexpectedly, the percentages of shared sequences between the tumor Treg samples were extremely high, reaching a maximum of 67.3% of shared sequences between tumor samples 3 and 5 data sets (Table 1 , top portion). In contrast, only 2 TCR aa sequences were common to the tumor and naive pLN data sets.
Three sequences were shared by all of the 6 tumor Treg samples analyzed and 3 other sequences were shared by 5 of the 6 tumor samples; all of these shared sequences were highly frequent (Table 1 , bottom portion). These sequences correspond to the definition of public TCR sequences, involving a dominant immune response to a specific epitope present in most individuals (25) . Furthermore, the 3 public sequences shared by all tumor samples only differed by a single amino acid and have a strong homology with 7 other tumor-shared sequences (Table 1 , bottom portion). The high percentage of homology between these public sequences and the other shared sequences strongly suggests that an antigen-driven process underlies the clonal expansions of Treg cells expressing different TCR sequences with similar antigenic specificities. Most of these public sequences were also identified in dLN Tregs from tumor-bearing mice, but not in naive pLN Treg cells (Table 1 , bottom portion). These findings imply that TAA recognition by Tregs, followed by clonal expansion, takes place within the tumor dLN before infiltrating the tumor tissue. For example, 77.7% of sequences from the tumor sample 2 Treg data set were also found in its corresponding dLN (Table 1 , top portion). Moreover, these BV-8.1 CDR3 aa public sequences arise from different nucleic acid sequences, suggesting that this antigen-driven mechanism leads to activation of diverse and different Treg clones (Supplementary Table 2 ).
To confirm our results, we carried out a similar CDR3 sequence analysis with the BV-6 family for which several distortions were also observed in CDR3 spectratyping profiles of tumor Treg cell samples ( Fig. 2D and Supplementary Fig.  S2F-H) . As previously shown for the BV-8.1 family, we observed a marked difference in the frequency of unique BV-6 CDR3 sequences obtained from tumor Treg samples versus tumor dLN and naive pLN (Supplementary Table S3 ). Several tumor Treg BV-6 CDR3 sequences were present at high frequencies; about 60% of unique CDR3 sequences were present at least 3 times. In contrast, most Treg BV-6 CDR3 sequences from tumor dLN and naive pLN were present only once or twice (82.5% and 79.2% of total sequences cloned, respectively). We then compared the 5 different tumor Treg cell data sets as well as the tumor dLN and naive pLN data sets (Supplementary Table S4 ). As expected, none of the sequences from the tumor or tumor dLN samples was shared with the naive pLN data sets. Although less pronounced than the results obtained for the BV-8.1 family, we observed that different tumor Treg data sets, obtained from independent experiments, shared several sequences (Supplementary Table S4 ). Five public sequences were also identified when analyzing these shared BV-6 CDR3 sequences from independent tumor Treg samples (Supplementary Table S5 ). These findings clearly confirmed our results obtained with the BV-8.1 family and support the hypothesis of an antigen-driven mechanism inducing Treg-cell infiltration of tumor tissue. One of the BV-6 CDR3 public sequences was identical to one of the most represented BV-8.1 CDR3 public sequences. This strengthens the hypothesis that tumor Treg cells, even those expressing different BV families of receptors, could potentially be activated by the same antigens. As previously observed for the BV-8.1 family, there was a high percentage of shared sequences between the tumor and the tumor dLN; around 60% of BV-6 CDR3 sequences found in Tregs from tumor sample 2 were also found in the corresponding tumor dLN (Supplementary Table S4 ). These results supported the hypothesis that antigen recognition by Treg cells occurs within tumor dLN before expansion and migration into the tumor.
Tumor Teff cells show biased TCR repertoire
We next analyzed the TCR repertoire of intratumoral Teff cells to determine whether public sequences could also be detected for these cells. Foxp3
þ T cells represented about 40% of tumor-infiltrating CD4 þ T cells (Fig. 1D) . As expected, Teff cells, from either control spleen or pLN, displayed a more naive phenotype than Treg cells, characterized by high expression of CD62L and low expression of CD44 and CD69 markers ( Supplementary Fig. S6A and B) . In contrast, tumor-infiltrating Teff cells, displayed the phenotypic characteristic of activated cells. For most BV, immunoscope profiles of tumor Teff cells presented severe distortions in CDR3 peak distribution ( Fig. 3D and Supplementary Fig. S6C-F) , characteristic of clonal expansions (Fig. 3E and F) when compared with the CDR3 profiles for naive spleen and pLN Teff samples (Fig. 3A and B). We then compared the BV-8.1 sequences obtained from all tumor samples in 6 independent experiments. The percentage of BV-8.1 CDR3 sequences common to all of the 6 analyzed tumor Teff cell data sets was surprisingly low (Supplementary Table S8A ). Only one TCR aa sequence, shared by 2 different tumor Teff data sets, could be detected (Supplementary Table S8B ). Furthermore, no shared CDR3 sequences between the different data sets for tumor Teff cells could be identified when analyzing the BV-6 family (data not shown). Thus, although biased immunoscope profiles were observed and a high number of sequence copies were detected-confirming the existence of clonal expansions-the antigen-driven process governing tumor Teff infiltration seems to be more diverse and polyspecific than for tumor Treg cells.
Tumor Teff and Treg cells display distinct TCR repertoires
Conversion of Teffs into Tregs, by the expression of the transcription factor Foxp3, could explain the high percentage of intratumoral Treg cells. To test this hypothesis, we compared for each independent experiment tumor Teff and Treg BV-8.1 TCR sequences (Table 2 ). Only 5 aa TCR sequences were shared by these 2 populations, and each shared sequence was identified for a single tumor sample. In addition, none of the public sequences identified for tumor Treg samples could be detected on tumor Teff samples. Identical results were obtained when comparing BV-6 CDR3 sequences obtained from tumor Treg and Teff cells (Supplementary Table S9 ). Only two sequences were shared by these 2 populations in only one tumor sample and at a low number of copies. These data strongly suggested that conversion is not an active process responsible for the accumulation of Treg cells into tumor tissue.
Public sequences is a general feature of tumorinfiltrating Tregs
We next determined whether the oligoclonal and biased TCR repertoire observed for TC-1 tumor-infiltrating Treg cells is intrinsic to the TC-1 tumor model or is a general feature of tumor-infiltrating Treg cells. To do this, we carried Us, total number of unique sequences shared; Ts, total number of clones sequenced coding for these shared sequences, found in each T-cell subset. The corresponding percentage among total clones sequenced is shown in parentheses. 5 MO-5 cells. Twenty days later, mice were killed and spleens, tumor-dLNs, and tumors were processed to obtain cell suspensions that were counted, stained, and analyzed by flow cytometry. Spleens and pLNs from naive Foxp3-GFP mice were identically processed and used as controls. A, percentage (mean AE SD) of CD45
þ cells expressing Foxp3 after FACS analysis, gated on live cells. Results represent pooled data from 3 independent experiments, n ¼ 4 (Spl N and Spl T), n ¼ 6 (pLN, dLN and tumor). ÃÃ , P < 0.01, as determined by one-way ANOVA. B, surface expression of CD62L, CD44, and CD69 molecules on CD4 AutoMacs CD4 þ cells enrichment, Foxp3-GFP þ Treg cells were FACS sorted, total RNA was purified, and reverse transcribed. The corresponding cDNA was subjected to quantitative PCR with primers specific to each BV family. The resulting products were then subjected to run-off reactions to obtain immunoscope profiles. The CDR3 length profiles from FACS sorted CD4 Immunoscope profiles from the various BV families presented severe distortions in CDR3 peak distributions (Fig. 4C and Supplementary Fig. S7C-E We then analyzed the CDR3 sequences from the BV-6 family that displayed biased CDR3 profiles in most of the MO-5 tumor Treg samples analyzed (Fig. 4C and Supplementary Fig. S7C -E) with one major CDR3 peak of 11 aa ( Fig. 4D and E) . Moreover, several unique BV-6 TCR sequences were present at very high frequency in MO-5 tumor Treg samples (Supplementary Table S11 ). Comparison of the BV-6 CDR3 data sets showed high percentages of shared sequences between the various MO-5 tumor Treg samples (Table 3 , top portion). Analysis of these sequences revealed several public sequences shared by 2 to 4 of the 6 MO-5 tumor Treg samples (Table 3 , middle, portion).
Finally, we compared BV-6 CDR3 sequences from TC-1 tumor Treg samples with those from MO-5 tumor Treg samples. Only one BV-6 CDR3 sequence was shared between both tumor models and was only present in 2 tumor samples (Table 3 , bottom portion). This shared sequence corresponded to a 9-aa CDR3 sequence, whereas all public sequences found in the MO-5 tumor model were 11-aa CDR3 sequences.
Discussion
The infiltration of tumor tissue by Treg cells has been widely reported in human cancers and in murine tumor models (8, 9) . However, the role played by this regulatory population in tumor tolerance/protection against immunotherapy remains unclear (26). Understanding the mechanisms by which Treg cells migrate and accumulate into the tumor tissue is of primary importance for the development of efficient immunotherapies.
We aimed to establish whether infiltration of tumor tissue by Tregs is due to either tumor inflammation promoting the migration and conversion of CD4 þ T cells into tumor tissue or to antigen-driven activation and expansion of Treg cells. To answer this question, we used the immunoscope technology to carry out a TCR repertoire diversity analysis of Treg and Teff populations in non-TCR-transgenic Foxp3-GFP knockin mice, bearing either TC-1 or MO-5 large solid tumors. The immunoscope technology enables the global analysis of a complete TCR repertoire without the need for high-throughput sequencing. Analysis of CDR3 peak lengths distribution for each BV family is a good indicator of T-cell repertoire diversity. Gaussian-like distributions of CDR3 peak lengths suggest a diverse repertoire (21, 27) . In contrast, distortions on CDR3 length profiles strongly indicate a biased repertoire due to clonal expansions. Such distortions have already been observed in allograft models (28) and chronic infections (19) . Our study represents the first analysis of the complete TCR repertoire of CD4 þ T cells in non-TCR transgenic mice expressing or not expressing the Foxp3-GFP transcription factor, using 2 different solid tumor models. The TCR repertoire of mouse Treg cells at steady state has been widely documented (29) . Our present study shows that Treg cells from splenic or pLNs harbor a very diverse repertoire, with CDR3 spectratyping profiles showing Gaussian distributions in all BV families, confirming earlier reports (30) . Treg CDR3 spectratyping profiles from the spleen or dLN from tumor-bearing mice showed no distortion and were comparable with those obtained from control samples. In agreement with other investigators, BV usage by Treg and Teff cells was similar (31) . In contrast, TC-1 tumor-infiltrating Treg and Teff cells displayed CDR3 spectratyping profiles characteristic of biased and strongly perturbed repertoires, typical of clonal expansions, suggesting that strong T-cell responses have occurred within the tumor tissue.
We observed an extremely high percentage of overlapping sequences when comparing the sequence data sets for tumorinfiltrating Treg cells CDR3 BV-8.1 aa TCR obtained from different individuals and independent experiments. This identified common TCR sequences, called "public sequences." The observation of these public TCRs is related to a process known as clonal dominance, corresponding to the dominance of a particular clonotype over others involved in an immune response to a specific epitope. Venturi and colleagues hypothesized that public sequences result from a mechanism called convergent recombination, in which the TCR diversity generated by V-D-J recombination leads to the same or similar nucleotide sequences in some cases (25) . We indeed showed that in the same individual, public TCR BV-8.1 sequences in tumor-infiltrating Treg cells shared the same amino acid sequence and were encoded by several distinct nucleic sequences. Most of these public TCR BV-8.1 sequences only differed by 1 or 2 amino acids, constituting consensus groups of amino acid motifs. Finally, not all of the public sequences observed within an individual correspond to one single clonotype expansion. This excludes the possibility that the sequence expansions we observed result from artifactual amplification.
In tumor-bearing mice, public sequences constituted a large percentage of CDR3 BV-8.1 TCR of intratumoral Treg cells, strongly suggesting that infiltration of tumor tissue by these cells after activation in the dLNs, following recognition of immunodominant antigens, is followed by an intense proliferation. This skews the initially highly diverse TCR repertoire toward a few dominant clones. This observation was not limited to the BV-8.1 family as public sequences and clonal expansions were also observed in the CDR3 aa TCR sequence data sets from the BV-6 family for tumor-infiltrating Treg cells.
In contrast with these results, no public sequences were observed in tumor-infiltrating Teff cells when analyzing BV-8.1 and BV-6 CDR3 sequences. However, CDR3 spectrotype distortions and clonal expansions were also detected in this T-cell subset. One possibility is that Teff cells that have recognized tumor cell antigens in the dLNs and have been recruited to the tumor site became rapidly exhausted. Another possibility is that Teff cells-specific to TC-1 antigens-recognize a more diverse set of epitopes compared with Treg cells. Alternatively, the high percentage of overlapping TCR sequences of tumorinfiltrating Tregs cells could be due to a smaller size of the Treg repertoire as compared with Teff cells. Finally, in this study, we only analyzed 2 different BV families, and we cannot exclude the existence of Teff cells public sequences in other BV families. was purified and reverse transcribed. The corresponding cDNA material was then subjected to quantitative PCR with primers specific to each BV family. BV-6 TCR qPCR products were cloned and sequenced. Then, the percentage of BV-6 TCR sequences coding for the same amino acid sequences between 2 samples was calculated as described in Table 1 It has been recently proposed that the rapid Treg recruitment and/or expansion into tumors is a consequence of early tumor cell recognition by memory Treg cells specific to self-antigens (10) . To address whether the public sequences detected in TC-1 tumor-infiltrating Treg cells reflect the expansion of self-reactive clonotypes, we carried out a similar Treg TCR repertoire analysis in another tumor model, MO-5. As with the TC-1 model, we observed several distortions in the CDR3 spectrotype profiles of most BV families in the MO-5 tumor model. Public sequences were also detected in the BV-6 CDR3 TCR data sets obtained from MO-5 tumor-infiltrating Treg cells. However, only one BV-6 CDR3 TCR aa sequence was shared between MO-5 and TC-1 tumor-infiltrating Treg cells. The demonstration that different public sequences have been selected in the TC-1 and MO-5 models suggests a process involving the recognition of specific tumor antigens rather than a mechanism driven by the recognition of autoantigens. Whether the biologic properties of the E6 and E7 HPV oncoproteins expressed by TC-1 cells, compared with ovalbumin expressed by MO5 cells, could affect this process, remains to be determined.
Public CD8 þ T-cell responses have been reported in the case of chronic and persistent viral infections (32) . In these studies, the demonstration of public TCR sequences was carried out in models in which a single or a few antigens are the main target of the immune system (33, 34 expression and suppressive functions in the periphery after Ag exposure under particular conditions, a process known as conversion (36) . The tumor microenvironment is considered to gather favorable conditions for conversion, such as inappropriate Ag presentation or high amounts of TGF-b (37, 38) . To address whether conversion takes place in the TC-1 tumor model, we compared TCR BV-8.1 sequences obtained from tumor-infiltrating Treg and Teff cells from the same mice. Very few sequences were shared between Treg and Teff tumorinfiltrating T cells and none corresponded to public sequences. Although we cannot exclude the possibility that identical sequences could have been identified in other BV families, these data strongly suggest that conversion is not an active process at the tumor site, at least in TC-1 tumor model. These results are consistent with several TCR repertoire analysis studies that conclude that Treg conversion is a rare event, occurring at low frequency at steady state (30, 39, 40) or in carcinogen-induced tumors (41) . However, one recent publication concluded that most Treg cells in tumors are likely generated by the conversion of effector CD4 þ T cells (35) . This may be because the study used TCR mini mice bearing B16 melanoma. Results obtained in a TCR transgenic mouse model could reflect biased observations due to the particular TCR specificity harbored by T cells.
Our study shows that a large proportion of tumor-infiltrating Treg sequences, especially those encoding public sequences, are found in the repertoire of Treg cells obtained from the dLNs. Treg cells may, therefore, be activated in the dLN, start their first round of proliferation, and then migrate to the tumor site, where they continue to proliferate and accumulate. However, an alternative scenario in which Tregs migrate from the tumors to lymphoid organs could not be excluded. Within the tumor site, clonal deletion or apoptosis of Teff cells may contribute to Treg cell expansion by allowing easier access to antigens. Alternatively, inside the tumor, Treg cells could accumulate by capturing IL-2 locally produced by activated Teff cells. Understanding the mechanisms promoting the expansion and survival of Treg inside the tumor and the antigens leading to clonal dominance and selection of public sequences is of primary importance to develop effective immunotherapy.
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